World News: 13:30 GMT Tuesday 3rd December 2019. [Green Hygienics Holdings Inc. via Globe Newswire via SPi World News]
SAN DIEGO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Green Hygienics Holdings Inc. (OTCQB: GRYN) (“GRYN” or the “Company”), an innovative premium cannabis cultivation and branding enterprise, is pleased to announce the appointment of Sid Senroy, MBA, as its Head of Quality and Compliance. In this advisory role, Senroy will enable the Company to form cross-functional alliances for improvement and growth as well as leverage existing company expertise, increased levels of productivity, compliance and efficiencies.
“This will directly support the Company to achieve its stated objectives to adhere to the highest standards of operations in consistently delivering safe and premium quality products to consumers and that the Company intends to be a leader in FDA cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace. We are very excited to have Mr. Senroy as part of the growing Green Hygienics team,” GRYN CEO Ron Loudoun stated.
As a seasoned business executive with an MBA from Pepperdine University, Senroy’s special expertise centers on helping companies pass compliance assessments, develop robust quality systems and prepare for U.S. Food and Drug Administration (“FDA”) reviews and inspections. His most recent accomplishment was the revamping of the quality and compliance program within the global R&D organization of a large biotechnology company, which led to successful FDA pre-approval inspections with no significant regulatory findings.
Over the past two decades, Senroy has successfully led several global Quality and Compliance business units as an executive or senior consultant, leading to the approval of key blockbuster drugs with cumulative sales exceeding $30 billion annually over the last 10 years. Senroy’s ability to form cross-functional alliances for improvement and growth, in addition to a sensitivity to cultural nuances, has helped him succeed on a global scale. He has worked extensively throughout North America, Europe, Asia and South America.
Senroy’s expertise includes: GXP Regulatory Compliance, Mock Inspection, Sarbanes Oxley, Auditing and PAI Readiness, SOP Management, Training Management, Quality Management Systems, Metrics and Reporting, Systems Development Lifecycle and IT.
Our mission is to grow the Company in a sustainable and profitable manner to be one of the largest industrial hemp for CBD producers in North America. The Company will adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers. The Company intends to be a leader in FDA cGMP (Current Good Manufacturing Practice) capabilities in the hemp and CBD marketplace.
The Company’s business model includes generating revenues from the sale of hemp and premium-grade CBD products; creating trusted global consumer brands; developing valuable IP; and growing the Company rapidly through strategic acquisitions.
For more information, visit:
Safe Harbor Statements Certain information contained in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects" or "does not expect," "is expected," "anticipates" or "does not anticipate," "plans," "estimates," "intends" or "believes," or that certain actions, events or results "may," "could," "would," "might" or "will be taken," "occur," or "be achieved." Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Globe Newswire: 13:30 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.